3,595 reports of this reaction
2.7% of all SOMATROPIN reports
#8 most reported adverse reaction
INJECTION SITE PAIN is the #8 most commonly reported adverse reaction for SOMATROPIN, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 3,595 FDA adverse event reports linking SOMATROPIN to INJECTION SITE PAIN. This represents approximately 2.7% of all 133,576 adverse event reports for this drug.
SOMATROPIN has an overall safety score of 78 out of 100. Patients taking SOMATROPIN who experience injection site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE PAIN is a less commonly reported adverse event for SOMATROPIN, but still significant enough to appear in the safety profile.
In addition to injection site pain, the following adverse reactions have been reported for SOMATROPIN:
The following drugs have also been linked to injection site pain in FDA adverse event reports:
INJECTION SITE PAIN has been reported as an adverse event in 3,595 FDA reports for SOMATROPIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE PAIN accounts for approximately 2.7% of all adverse event reports for SOMATROPIN, making it a notable side effect.
If you experience injection site pain while taking SOMATROPIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.